Protein Sciences, U.S. Department of Health and Human Services deal
Protein Sciences said HHS’ Biomedical Advanced Research and Development Authority (BARDA) exercised the second of two option periods under a 2009 contract to manufacture flu vaccines. The company said the option period has a budget of $50.6 million and will run through Dec. 31, 2015. Protein Sciences said the funds will support licensure of a facility in Pearl River, N.Y., that manufactures Flublok seasonal influenza vaccine and is planned to have the capacity to produce 50 million doses of Panblok pandemic influenza vaccine within 6 months of a pandemic declaration. The funds will also be used for clinical studies to support licensure of Panblok and a quadrivalent formulation of Flublok. The total value of the contract is $146.9 million. Protein Sciences said BARDA amended the contract to lengthen the first of the two option periods in February 2013 (see BioCentury, March 4, 2013). ...